Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05204927 · ClinicalTrials.gov registry record · Phase 3
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
A Phase 3 study of Metastasis From Malignant Tumor of Prostate, sponsored by Curium US.
- Active
- Registry status
- Phase 3
- Development phase
- 439
- Enrollment target
- 20
- Study locations
NCT05204927 is a Phase 3 study of Metastasis From Malignant Tumor of Prostate that is active but no longer recruiting, run by Curium US. The registered enrollment target is 439 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT05204927, a Phase 3 study of Metastasis From Malignant Tumor of Prostate, is active but no longer recruiting, sponsored by Curium US.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 439 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Conditions Studied
Interventions
- DRUG 177Lu-PSMA-I&T
- DRUG Abiraterone with Prednisone or Enzalutamide
Study Locations (20)
California
- Providence Medical Foundation - Fullerton
- Long Beach Memorial Center - Long Beach
- Hoag Memorial Hospital Presbyterian - Newport Beach
- San Francisco VA Health Care System - San Francisco
- University of California, San Francisco - San Francisco
- Providence Saint John's Health Center - Santa Monica
Florida
- GenesisCare USA - Boca Raton
- Biogenix Molecular LLC - Miami
- Orlando Health Cancer Institute - Orlando
- GenesisCare USA - Plantation
- Florida Urology Partners, LLP - Tampa
Michigan
- Henry Ford Hospital - Detroit
- BAMF Health I PC - Grand Rapids
- Michigan Institute of Urology - Troy
- GenesisCare USA - Troy
Illinois
- Northwestern Memorial Hospital - Chicago
- NorthShore University HealthSystem-Evanston Hospital - Evanston
Maryland
- John Hopkins Hospital - Baltimore
- Kaiser Permanente Gaithersburg Medical Center - Gaithersburg
Arizona
- Arizona Institute of Urology, PPLC - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 439 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2029-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05204927
The ClinicalTrials.gov registry entry for NCT05204927 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 439 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Curium US, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastasis From Malignant Tumor of Prostate appearing as the primary indexed condition, and to 2 interventions - of which 177Lu-PSMA-I&T is the first listed.
NCT05204927 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT05204927 about?
NCT05204927 is a clinical study titled "177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer". A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
What is the current status of trial NCT05204927?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 439 participants. The study started on 2022-02-14. Estimated completion is 2029-02.
What conditions does trial NCT05204927 study?
This clinical trial studies the following conditions: Metastasis From Malignant Tumor of Prostate.
What interventions are being tested in trial NCT05204927?
The interventions under investigation include: 177Lu-PSMA-I&T (DRUG), Abiraterone with Prednisone or Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT05204927?
This trial is sponsored by Curium US, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05204927 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.